MedPath

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Hypertension
Interventions
Registration Number
NCT02182830
Lead Sponsor
Boehringer Ingelheim
Brief Summary

This trial is designed to investigate the efficacy and safety of empagliflozin compared with placebo in hypertensive black/African Americans with type 2 Diabetes Mellitus. Since hyperglycaemia and hypertension are key risk factors for both micro- and macrovascular complications, assessment of both glucose and BP lowering effects of empagliflozin in hypertensive African American patients with type 2 Diabetes Mellitus could provide clinically highly relevant, new information for the use of empagliflozin.

Essential hypertension is four times more common in African Americans than in Caucasians.

One of the risk factors for hypertension is sodium sensitivity and approximately one third of the essential hypertensive population is responsive to sodium intake. There is a higher association of hypertension with sodium sensitivity in African American patients with type 2 Diabetes Mellitus.

The treatment duration of this trial (24 weeks) will enable assessment of the clinically relevant endpoint of a decrease in HbA1c, a well accepted measurement of chronic glycaemic control and the key secondary endpoints of decreases in systolic BP (SBP) and diastolic BP (DBP) at 12 and 24 weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
166
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
EmpagliflozinEmpagliflozin low dosestarting dose 10mg; forced titration after 4 weeks 25mg dose
Placeboplacebostarting dose 10mg; forced titration after 4 weeks 25mg dose
EmpagliflozinEmpagliflozin high dosestarting dose 10mg; forced titration after 4 weeks 25mg dose
Primary Outcome Measures
NameTimeMethod
Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeksbaseline and 24 weeks

Change from baseline in HbA1c (%) at 24 weeks is presented. The term "baseline" refers to the last observation prior to randomisation of the patient.

Means presented are the adjusted means. Restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) model is used in the statistical analysis.

Secondary Outcome Measures
NameTimeMethod
Changes From Baseline in Trough Mean Ambulatory SBP at Week 12baseline and 12 weeks

Changes from baseline in trough mean ambulatory SBP at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient.

Means presented are the adjusted means. This is a key secondary endpoint

Change From Baseline in Body Weight at Week 24baseline and 24 weeks

Changes from baseline in body weight at Week 24 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient.

Means presented are the adjusted means. This is a key secondary endpoint

Change From Baseline in Trough Seated SBP at Week 12baseline and 12 weeks

Change from baseline in trough seated SBP (mmHg) at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient.

Means presented are the adjusted means. This is a key secondary endpoint

Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (SBP) at Week 12baseline and 12 weeks

Change from baseline in mean 24-hour ambulatory Systolic blood pressure SBP at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient.

Means presented are the adjusted means. This is a key secondary endpoint

Change From Baseline in Mean 24-hour Ambulatory SBP (mmHg) at Week 24baseline and 24 weeks

Change from baseline in mean 24-hour ambulatory SBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient.

Means presented are the adjusted means.

Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (DBP) at Week 12baseline and 12 weeks

Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 12. The term "baseline" refers to the last observation prior to randomisation of the patient.

Means presented are the adjusted means.

Change From Baseline in Mean 24-hour Ambulatory DBP (mmHg) at Week 24baseline and 24 weeks

Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient.

Means presented are the adjusted means.

Change From Baseline in Trough Seated SBP (mmHg) at Week 24baseline and 24 weeks

Change from baseline in trough seated SBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient.

Means presented are the adjusted means.

Change From Baseline in Trough Seated DBP (mmHg) at Week 12baseline and 12 weeks

Change from baseline in trough seated DBP (mmHg) at Week 12 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient.

Means presented are the adjusted means.

Change From Baseline in Trough Seated DBP (mmHg) at Week 24baseline and 24 weeks

Change from baseline in trough seated DBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient.

Means presented are the adjusted means.

Trial Locations

Locations (89)

Atlanta Clinical Research Centers

🇺🇸

Atlanta, Georgia, United States

Albert F. Johary MD, PC

🇺🇸

Dunwoody, Georgia, United States

University of Chicago

🇺🇸

Chicago, Illinois, United States

University of South Alabama

🇺🇸

Mobile, Alabama, United States

Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC

🇺🇸

Marietta, Georgia, United States

Longwood Research

🇺🇸

Huntsville, Alabama, United States

MD Clinical Trials

🇺🇸

Los Angeles, California, United States

Long Beach Center for Clinical Research

🇺🇸

Long Beach, California, United States

Office of Dr. Alexander Ford, M.D.

🇺🇸

Los Angeles, California, United States

Orange County Research Center

🇺🇸

Tustin, California, United States

UF Health Jacksonville

🇺🇸

Jacksonville, Florida, United States

Care Partners Clinical Research LLC

🇺🇸

Jacksonville, Florida, United States

Morehouse School of Medicine

🇺🇸

Atlanta, Georgia, United States

Grady Memorial Hospital

🇺🇸

Atlanta, Georgia, United States

John H. Stroger Jr. Hospital of Cook Country

🇺🇸

Chicago, Illinois, United States

Mercy Research

🇺🇸

Washington, Missouri, United States

University of Maryland School of Medicine

🇺🇸

Baltimore, Maryland, United States

Metrolina Internal Medicine, PA

🇺🇸

Charlotte, North Carolina, United States

High Point Clinical Trials Center

🇺🇸

High Point, North Carolina, United States

Laurelton Heart Specialist, PC

🇺🇸

Rosedale, New York, United States

Temple University School of Medicine

🇺🇸

Philadelphia, Pennsylvania, United States

Hometown Urgent Care

🇺🇸

Columbus, Ohio, United States

TLM Medical Services, LLC

🇺🇸

Columbia, South Carolina, United States

The Green Clinic PC

🇺🇸

Memphis, Tennessee, United States

Kelsey-Seybold Clinic

🇺🇸

Houston, Texas, United States

Hillcrest Family Health Center

🇺🇸

Waco, Texas, United States

Cullen Family Practice, PLLC

🇺🇸

Houston, Texas, United States

Texas Center for Drug Development, Inc.

🇺🇸

Houston, Texas, United States

Clinical Research Partners, LLC

🇺🇸

Richmond, Virginia, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Lynn Institute of Denver

🇺🇸

Denver, Colorado, United States

Meridien Research

🇺🇸

Tampa, Florida, United States

Quality Clinical Research Inc

🇺🇸

Omaha, Nebraska, United States

Family Medical Clinic

🇺🇸

Milwaukee, Wisconsin, United States

eStudySite

🇺🇸

Chula Vista, California, United States

Pines Clinical Research Inc.

🇺🇸

Hollywood, Florida, United States

Sunshine Research Center

🇺🇸

Opa-locka, Florida, United States

Atlanta Center

🇺🇸

Atlanta, Georgia, United States

Alternative Solutions Medical Research and Prevention Center

🇺🇸

Saint Petersburg, Florida, United States

Accord Clinical Research, LLC

🇺🇸

Port Orange, Florida, United States

Cedar Crosse Research Center

🇺🇸

Chicago, Illinois, United States

Centex Studies, Inc.

🇺🇸

Houston, Texas, United States

PhysiqueMed Clinical Trials

🇺🇸

Greensboro, North Carolina, United States

Lovelace Scientific Resources, Inc.

🇺🇸

Albuquerque, New Mexico, United States

Peters Medical Research

🇺🇸

High Point, North Carolina, United States

Diagnostic Clinic of Houston

🇺🇸

Houston, Texas, United States

Dayton Clinical Research

🇺🇸

Dayton, Ohio, United States

Suburban Research Associates

🇺🇸

Media, Pennsylvania, United States

York Clinical Research, LLC

🇺🇸

Norfolk, Virginia, United States

Dominion Medical Associates, Inc.

🇺🇸

Richmond, Virginia, United States

Erie County Medical Center

🇺🇸

Buffalo, New York, United States

Medex Healthcare Research, Inc.

🇺🇸

New York, New York, United States

Offic of Dr. Eric Cheng

🇺🇸

Brooklyn, New York, United States

Internal Medicine Center, LLC

🇺🇸

Mobile, Alabama, United States

Integrated Research Group, Inc.

🇺🇸

Riverside, California, United States

Healthwise Medical Associates

🇺🇸

Brooklyn, New York, United States

Larry Watkins, M .D.

🇺🇸

Little Rock, Arkansas, United States

Modern Medical

🇺🇸

Brooklyn, New York, United States

Investigators Research Group, LLC

🇺🇸

Brownsburg, Indiana, United States

Torrance Clinical Research Institute Inc.

🇺🇸

Lomita, California, United States

Eagle's Landing Diabetes and Endocrinology

🇺🇸

Stockbridge, Georgia, United States

New Orleans Center for Clinical Research

🇺🇸

New Orleans, Louisiana, United States

Sestron Clinical Research

🇺🇸

Marietta, Georgia, United States

American Institute of Research Studies

🇺🇸

Baltimore, Maryland, United States

WR-Mount Vernon Clinical Research, LLC

🇺🇸

Sandy Springs, Georgia, United States

Phillips Medical Services, PLLC

🇺🇸

Jackson, Mississippi, United States

Today Clinical Research, Oklahoma City

🇺🇸

Oklahoma City, Oklahoma, United States

Coastal Carolina Health Care, P.A.

🇺🇸

New Bern, North Carolina, United States

Berkley Family Practice

🇺🇸

Moncks Corner, South Carolina, United States

Amistad Clinical Research Center

🇺🇸

Columbia, South Carolina, United States

Millennium Clinical Trials LLC

🇺🇸

Arlington, Virginia, United States

Diabetes Associates Medical Group

🇺🇸

Orange, California, United States

Mobile Medical and Diagnostic Center

🇺🇸

Mobile, Alabama, United States

Scott Research, Inc.

🇺🇸

Laurelton, New York, United States

Triad Clinical Trials

🇺🇸

Greensboro, North Carolina, United States

Clinical Trials Research

🇺🇸

Sacramento, California, United States

Central Florida Internist

🇺🇸

Orlando, Florida, United States

Accent Clinical Trials

🇺🇸

Las Vegas, Nevada, United States

Cardiology and Medicine Clinic

🇺🇸

Little Rock, Arkansas, United States

Medical Research South

🇺🇸

Charleston, South Carolina, United States

Greenville Pharmaceutical Rsch

🇺🇸

Greenville, South Carolina, United States

Mountain View Clinical Research

🇺🇸

Greer, South Carolina, United States

Community Research Partners, Inc

🇺🇸

Varnville, South Carolina, United States

Southwind Medical Specialists

🇺🇸

Memphis, Tennessee, United States

University of Tennessee

🇺🇸

Memphis, Tennessee, United States

Gulf Regional Research and Education Services, LLC

🇺🇸

Metairie, Louisiana, United States

Memphis Veterans Affairs Medical Center

🇺🇸

Memphis, Tennessee, United States

International Clinical Research - US, LLC

🇺🇸

Sanford, Florida, United States

Carolina Cardiology Clinical Research Institute, LLC

🇺🇸

Rock Hill, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath